Psyence Biomedical ( NASDAQ: PBM ) on Friday said it has decided not to proceed with the acquisition of Clairvoyant Therapeutics at this time. PBM +2.89% after hours to $0.
103. Earlier in September, Psyence Biomedical said it has entered into a term sheet with privately held Clairvoyant Therapeutics to acquire 100% of its shareholding. Source: Press Release More on Psyence Biomedical Ltd.
Psyence Biomedical receives delisting determination from Nasdaq Psyence Biomedical to acquire drug developer Clairvoyant Financial information for Psyence Biomedical Ltd..
